Registerplattform Urologischer Krebs (CARAT)

Adult patients with locally advanced and inoperable, or metastatic Renal Cell Carcinoma (aRCC); locally advanced and inoperable, or metastatic Urothelial Cancer (including Bladder Cancer) (aUBC); High-risk Muscle-Invasive Urothelial Carcinoma (High-risk MIUC); or patients with Muscle-Invasive Bladder Cancer (MIBC).

Inclusion Criteria:

Cohorts aRCC and aUBC (prospective)

• Female and male patients with aRCC or aUBC (locally advanced, inoperable or metastatic)

• Patients at start of their first-line systemic treatment for aRCC or aUBC

• Written informed consent

  • Patients participating in the PRO module: signing of in-formed consent form and completion of baseline questionnaire before start of initial systemic treatment
  • Patients not participating in the PRO module: within twelve weeks after start of systemic first-line for aRCC or aUBC

• Age ≥ 18 years

Cohort High-risk MIUC (prospective and retrospective)

• Histologically proven muscle-invasive urothelial carcinoma (MIUC) of the lower or upper urinary tract (ICD-10 C65, C66, C67.x, C68.x). Mixed histologies are allowed (main compo-nent must be urothelial carcinoma, with minor variants accept-ed).

• Radical surgery (e.g., radical cystectomy, nephroureterecto-my) between October 1, 2021 and October 31, 2024.

• High-risk of recurrence, defined as follows: Post-operative, pathological tumor status

  • ypT2-ypT4 and/or ypN+ and without clinically detectable metastases (M0) at cystectomy for patients with prior neo-adjuvant chemotherapy or
  • pT3-pT4 and/or pN+ and without clinically detectable me-tastases (M0) at cystectomy for patients without prior neo-adjuvant chemotherapy.

• Age ≥ 18 years at the time of surgery.

• Written informed consent (only if patient is alive at time of data entry; not applicable for inclusion of deceased patients' data)

Cohort MIBC (prospective)

• Diagnosis of MIBC (muscle-invasive bladder cancer; ICD-10 C67.x; cT2-T4aN0M0 or T1-T4aN1M0).
• Histologically proven muscle-invasive urothelial carcinoma. Mixed histologies are allowed (main component must be urothelial histology, with minor variants accepted).
• Age ≥ 18 years at the time of diagnosis.
• Written informed consent within 15 weeks from diagnosis of MIBC.

Exclusion Criteria:

Cohorts aRCC and aUBC (prospective)

• Patients with prior systemic therapy for aRCC or aUBC
• No systemic treatment for aRCC or aUBC

Cohort High-risk MIUC (prospective and retrospective)

• Partial cystectomy or partial nephrectomy of the primary tumor as definitive therapy
• Metastatic disease (M1) at the time of surgery

Cohort MIBC (prospective)

• Clinically detectable metastases (M1) at the time of diagnosis.
• Treatment in palliative intention (for tumors considered inoperable).